-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] On the evening of April 14, while disclosing the 2021 annual report, the in vitro diagnostic company Shuo Shi Bio also announced the annual dividend plan, which plans to distribute 100 yuan for every 10 shares
.
The company's 2021 annual report shows that the company's operating income in 2021 will be about 2.
839 billion yuan, a year-on-year increase of 63.
19%; the net profit attributable to shareholders of listed companies is about 1.
193 billion yuan, a year-on-year increase of 45.
59%; basic earnings per share are 20.
36 yuan, a year-on-year increase.
An increase of 45.
64%
.
At the same time, the company will distribute dividends generously.
It plans to distribute a cash dividend of 100 yuan (tax included) for every 10 shares, with a total proposed cash dividend of 586 million yuan (tax included), accounting for nearly half of the net profit in 2021 and accounting for the undistributed profit as of 2021.
36.
33%
.
It is reported that as of March 31, 2022, there are 15,300 shareholders of Shuo Shi Bio, and based on this calculation, the company can receive an average dividend of 38,000 yuan per person
.
According to the data, Shuo Shi Bio is a company with both nucleic acid and antigen detection product lines in China.
The substantial increase in the company's revenue in 2021 is mainly driven by the expansion of demand for detection reagents and other related products
.
From the perspective of the in vitro diagnostic industry that Shuo Shi Bio belongs to, in vitro diagnosis plays an important role in the whole process of disease prevention, diagnosis, monitoring and guidance of treatment
.
China's in vitro diagnostic industry started late, but with the growth of the population and the intensification of aging, the industry has developed rapidly, especially since 2020, under the overweight of a series of favorable policies, the research and development of domestic in vitro diagnostics has increased, and self-sufficiency has been achieved.
The pace of import substitution has been accelerated, and the entire industry has ushered in rapid development
.
Statistics show that in 2020, China's in vitro diagnostic market will reach 89 billion yuan
.
Driven by factors such as technological innovation, aging population, and growth in per capita disposable income, it is expected that China's IVD industry will continue to grow in the future.
.
Up to now, in addition to Shuo Shi Bio, some in vitro diagnostic companies have also disclosed annual distribution plans since March, many of which include cash dividends
.
For example, Wantai Bio announced on April 15 that the profit distribution and share capital increase will be based on the company's total share capital of 607 million shares before the implementation of the plan, and a cash dividend of 0.
2 yuan (tax included) will be distributed per share, and bonus shares will be distributed per share.
0.
2 shares, and 0.
25 shares per share from the capital reserve, a total of 1.
214 billion cash dividends were distributed, 121 million bonus shares were distributed, and 152 million shares were transferred.
The total share capital after this distribution is 880 million shares
.
The company is mainly engaged in the research and development, production and sales of in vitro diagnostic reagents, instruments and vaccines
.
Daan Gene announced the 2021 annual dividend plan on March 31: Based on 1.
403 billion shares, a cash dividend of 11.
1 yuan (tax included) will be distributed to all shareholders for every 10 shares, with a total cash dividend of 1.
558 billion yuan
.
According to the data, Daan Gene is a molecular diagnostic technology-led company that integrates the research and development, production and sales of clinical test reagents, instruments and supporting consumables
.
Leadman also disclosed the 2021 annual dividend plan on March 19: Based on 544 million shares, a cash dividend of 0.
2 yuan (tax included) will be distributed to all shareholders for every 10 shares, with a total cash dividend of 10.
8802 million yuan
.
It is reported that Leadman is an in vitro diagnostic product enterprise engaged in the research and development, production and sales of biochemical diagnostic reagents earlier in China.
Its main business currently covers three major fields of in vitro diagnostic reagents, diagnostic instruments and biochemical raw materials
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
The company's 2021 annual report shows that the company's operating income in 2021 will be about 2.
839 billion yuan, a year-on-year increase of 63.
19%; the net profit attributable to shareholders of listed companies is about 1.
193 billion yuan, a year-on-year increase of 45.
59%; basic earnings per share are 20.
36 yuan, a year-on-year increase.
An increase of 45.
64%
.
At the same time, the company will distribute dividends generously.
It plans to distribute a cash dividend of 100 yuan (tax included) for every 10 shares, with a total proposed cash dividend of 586 million yuan (tax included), accounting for nearly half of the net profit in 2021 and accounting for the undistributed profit as of 2021.
36.
33%
.
It is reported that as of March 31, 2022, there are 15,300 shareholders of Shuo Shi Bio, and based on this calculation, the company can receive an average dividend of 38,000 yuan per person
.
According to the data, Shuo Shi Bio is a company with both nucleic acid and antigen detection product lines in China.
The substantial increase in the company's revenue in 2021 is mainly driven by the expansion of demand for detection reagents and other related products
.
From the perspective of the in vitro diagnostic industry that Shuo Shi Bio belongs to, in vitro diagnosis plays an important role in the whole process of disease prevention, diagnosis, monitoring and guidance of treatment
.
China's in vitro diagnostic industry started late, but with the growth of the population and the intensification of aging, the industry has developed rapidly, especially since 2020, under the overweight of a series of favorable policies, the research and development of domestic in vitro diagnostics has increased, and self-sufficiency has been achieved.
The pace of import substitution has been accelerated, and the entire industry has ushered in rapid development
.
Statistics show that in 2020, China's in vitro diagnostic market will reach 89 billion yuan
.
Driven by factors such as technological innovation, aging population, and growth in per capita disposable income, it is expected that China's IVD industry will continue to grow in the future.
.
Up to now, in addition to Shuo Shi Bio, some in vitro diagnostic companies have also disclosed annual distribution plans since March, many of which include cash dividends
.
For example, Wantai Bio announced on April 15 that the profit distribution and share capital increase will be based on the company's total share capital of 607 million shares before the implementation of the plan, and a cash dividend of 0.
2 yuan (tax included) will be distributed per share, and bonus shares will be distributed per share.
0.
2 shares, and 0.
25 shares per share from the capital reserve, a total of 1.
214 billion cash dividends were distributed, 121 million bonus shares were distributed, and 152 million shares were transferred.
The total share capital after this distribution is 880 million shares
.
The company is mainly engaged in the research and development, production and sales of in vitro diagnostic reagents, instruments and vaccines
.
Daan Gene announced the 2021 annual dividend plan on March 31: Based on 1.
403 billion shares, a cash dividend of 11.
1 yuan (tax included) will be distributed to all shareholders for every 10 shares, with a total cash dividend of 1.
558 billion yuan
.
According to the data, Daan Gene is a molecular diagnostic technology-led company that integrates the research and development, production and sales of clinical test reagents, instruments and supporting consumables
.
Leadman also disclosed the 2021 annual dividend plan on March 19: Based on 544 million shares, a cash dividend of 0.
2 yuan (tax included) will be distributed to all shareholders for every 10 shares, with a total cash dividend of 10.
8802 million yuan
.
It is reported that Leadman is an in vitro diagnostic product enterprise engaged in the research and development, production and sales of biochemical diagnostic reagents earlier in China.
Its main business currently covers three major fields of in vitro diagnostic reagents, diagnostic instruments and biochemical raw materials
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
